Screening of Fabry Disease in Portuguese Patients With Idiopathic Cardiomyopathies

NCT05409846 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 409

Last updated 2025-10-02

No results posted yet for this study

Summary

In Portugal, the prevalence of Fabry disease is largely unknown as recently has been stressed by the Portuguese hypertrophic cardiomyopathy registry investigators.

On the other hand, few data on Fabry screening protocols in patients with compromised ejection fraction including burned-out hypertrophic cardiomyopathy series have been published.

This project intends to perform screening of Fabry disease in patients with distinct cardiomyopathy phenotypes of unknown or dubious etiology and explore the less knew impact of the disease in other cardiac phenotypes.

Conditions

Interventions

DIAGNOSTIC_TEST

Alfa-galactosidase activity and genetic testing for Fabry diagnosis

Dry blood spot analysis and blood sample (if necessary)

Sponsors & Collaborators

  • Centro Hospitalar De São João, E.P.E.

    collaborator OTHER
  • Hospital Pedro Hispano

    collaborator OTHER
  • Centro Hospitalar do Tâmega e Sousa, Hospital Padre Américo

    collaborator UNKNOWN
  • Hospital da Luz, Lisboa

    collaborator UNKNOWN
  • Centro Hospitalar De Trás-Os-Montes E Alto Douro, E.P.E.

    collaborator UNKNOWN
  • Centro Hospitalar Universitário Lisboa Norte, EPE., Hospital de Santa Maria

    collaborator UNKNOWN
  • Centro Hospitalar de Entre Douro e Vouga, E.P.E., Hospital São Sebastião

    collaborator UNKNOWN
  • Centro Hospitalar Universitário de Coimbra

    collaborator UNKNOWN
  • Centro Hospitalar de Vila Nova de Gaia e Espinho, E.P.E.

    collaborator UNKNOWN
  • Centro Hospitalar Universitário de Santo António

    collaborator OTHER
  • Centro de Investigação em Tecnologias e Serviços de Saúde

    collaborator OTHER
  • Rede de Investigação em Saúde

    collaborator OTHER
  • Universidade do Porto

    lead OTHER

Principal Investigators

  • Elisabete Martins, MD, PhD · Universidade do Porto

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-15
Primary Completion
2025-01-01
Completion
2025-04-15

Countries

  • Portugal

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05409846 on ClinicalTrials.gov